Advanced in Virilizing Ovarian Tumor

Dr. Babak Edraki

Obstetrics and Gynecology | Oncology | Gynecologic Oncology
John Muir Physician Network
2400 Balfour Rd, Suite 120, 
Brentwood, CA 
 (2432.2 mi)
Offers Telehealth
Advanced in Virilizing Ovarian Tumor
John Muir Physician Network
2400 Balfour Rd, Suite 120, 
Brentwood, CA 
 (2432.2 mi)
OverviewInsuranceLocationsClinical Research

Overview

Babak Edraki is an Obstetrics and Gynecologist and an Oncologist in Brentwood, California. Dr. Edraki and is rated as an Advanced provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Ovarian Carcinosarcoma, Endometrial Stromal Sarcoma, Hernia Surgery, and Ureteral Reconstruction.

His clinical research consists of co-authoring 5 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Obstetrics and Gynecology
Oncology
Gynecologic Oncology
Licenses
Obstetrics & Gynecology in CA
Hospital Affiliations
Adventist Health Sonora
John Muir Medical Center - Walnut Creek Campus
John Muir Medical Center - Concord Campus
Languages Spoken
English
Farsi
French
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  Humana

Locations

JOHN MUIR PHYSICIAN NETWORK
2400 Balfour Rd, Suite 120, Brentwood, CA 94513
Other Locations
JOHN MUIR PHYSICIAN NETWORK
177 La Casa Via, Suite 200e, Walnut Creek, CA 94598

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
A Randomized Phase II Trial of Triplet Therapy (A PD-L1 Inhibitor Durvalumab (MEDI4736) in Combination With Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women With Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
Enrollment Status: Active_not_recruiting
Publish Date: February 10, 2025
Intervention Type: Procedure, Drug, Biological
Study Drugs: Cediranib Maleate, Durvalumab, Olaparib, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride, Topotecan Hydrochloride
Study Phase: Phase 2
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
A Phase III Randomized Trial of Radiation +/- Pembrolizumab (MK-3475) for Newly Diagnosed Early Stage High Intermediate Risk Mismatch Repair Deficient (dMMR) Endometrioid Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: February 06, 2025
Intervention Type: Other, Procedure, Radiation, Biological
Study Drug: Pembrolizumab
Study Phase: Phase 3
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
A Randomized, Phase II/III Study of Pegylated Liposomal Doxorubicin and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin, CTEP-Supplied Bevacizumab and CTEP-Supplied Atezolizumab Versus Pegylated Liposomal Doxorubicin and CTEP-Supplied Bevacizumab in Platinum Resistant Ovarian Cancer
Enrollment Status: Active_not_recruiting
Publish Date: November 08, 2023
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Atezolizumab, Bevacizumab, Pegylated liposomal doxorubicin hydrochloride
Study Phase: Phase 2/Phase 3
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma
Enrollment Status: Completed
Publish Date: May 17, 2023
Intervention Type: Drug
Study Drugs: Carboplatin/Paclitaxel, Trastuzumab
Study Phase: Phase 2
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
A Phase III Randomized, Placebo-Controlled Study of Pembrolizumab (MK-3475, NSC #776864) in Addition to Paclitaxel and Carboplatin for Measurable Stage III or IVA, Stage IVB or Recurrent Endometrial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: May 16, 2023
Intervention Type: Other, Drug, Procedure, Biological
Study Drugs: Carboplatin, Paclitaxel, Pembrolizumab
Study Phase: Phase 3
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
A Phase III Trial of Adjuvant Chemotherapy Following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial
Enrollment Status: Completed
Publish Date: November 07, 2022
Intervention Type: Other, Drug, Radiation
Study Drugs: Carboplatin, Cisplatin, Paclitaxel
Study Phase: Phase 3
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy (NCT #01101451)
Enrollment Status: Unknown
Publish Date: May 24, 2022
Intervention Type: Other, Radiation, Drug
Study Drug: Cisplatin
Study Phase: Phase 3
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
A Randomized Surgical Window Pilot Investigation of the Relationship of Short Term Medroxyprogesterone Acetate (NSC #26386) Compared to Medroxyprogesterone Acetate Plus Entinostat (NSC #706995) on the Morphologic, Biochemical, and Molecular Changes in Primary Endometrioid Adenocarcinoma of the Uterine Corpus
Enrollment Status: Completed
Publish Date: November 16, 2021
Intervention Type: Procedure, Drug, Other
Study Phase: Early Phase 1
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Enrollment Status: Completed
Publish Date: October 20, 2021
Intervention Type: Drug
Study Phase: Phase 2
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) Versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer
Enrollment Status: Unknown
Publish Date: September 30, 2021
Intervention Type: Other, Drug
Study Drugs: Carboplatin, Metformin hydrochloride, Paclitaxel
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

5 Total Publications

Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Homologous recombination deficiency should be tested for in patients with advanced stage high-grade serous ovarian cancer aged 70 years and over.
Journal: Gynecologic oncology
Published: March 17, 2024
Similar Doctors
Distinguished in Virilizing Ovarian Tumor
Dr. Amer Karam
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. Amer Karam
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (41.6 mi)
650-723-4000
Languages Spoken:
English
Offers Telehealth

Amer Karam is a Gynecologic Oncologist and an Oncologist in Stanford, California. Dr. Karam and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Endometrial Cancer, Vulvar Cancer, Ovarian Cancer, Oophorectomy, and Hysterectomy.

Distinguished in Virilizing Ovarian Tumor
Dr. Lee-may Chen
Gynecologic Oncology | Obstetrics and Gynecology | Oncology
Distinguished in Virilizing Ovarian Tumor
Dr. Lee-may Chen
Gynecologic Oncology | Obstetrics and Gynecology | Oncology

Ucsf Medical Group Business Services

505 Parnassus Ave, M1490, 
San Francisco, CA 
 (41.0 mi)
415-472-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Lee-may Chen is a Gynecologic Oncologist and an Obstetrics and Gynecologist in San Francisco, California. Dr. Chen and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. Her top areas of expertise are Desmoplastic Small Round Cell Tumor, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Hernia Surgery.

Distinguished in Virilizing Ovarian Tumor
Dr. John K. Chan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology
Distinguished in Virilizing Ovarian Tumor
Dr. John K. Chan
Gynecologic Oncology | Oncology | Obstetrics and Gynecology

Sutter Bay Medical Foundation

3838 California St, Rm 410, 
San Francisco, CA 
 (40.6 mi)
415-751-1847
Languages Spoken:
English
Offers Telehealth

John Chan is a Gynecologic Oncologist and an Oncologist in San Francisco, California. Dr. Chan and is rated as a Distinguished provider by MediFind in the treatment of Virilizing Ovarian Tumor. His top areas of expertise are Adult Soft Tissue Sarcoma, Ovarian Carcinosarcoma, Sertoli-Leydig Cell Tumor, Oophorectomy, and Bladder Reconstruction.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile